Silvio E. Inzucchi MDProfessor of Medicine (Endocrinology); Clinical Director, Section of Endocrinology; Director, Yale Diabetes Center; Director, Endocrinology and Metabolism Fellowship, Yale School of Medicine, New Haven, Connecticut
Dr. Silvio Inzucchi is professor of medicine at the Yale University School of Medicine in New Haven, Connecticut, where he serves as the clinical chief of the Section of Endocrinology, program director of the Endocrinology and Metabolism Fellowship, and the medical director of the Yale Diabetes Center.
Dr. Inzucchi received his medical degree from Harvard Medical School, in Boston, Massachusetts. He completed his residency in internal medicine and his post-doctoral fellowship in endocrinology and metabolism at Yale–New Haven Hospital.
Dr. Inzucchi has been an invited lecturer, both nationally and internationally, on many topics, most pertaining to clinical diabetes management. He has authored or coauthored more than 500manuscripts, chapters, and abstracts, some published in the foremost medical journals, including The New England Journal of Medicine and JAMA. He has served on editorial boards for numerous scientific journals, including Diabetes Care and the Journal of Clinical Endocrinology & Metabolism.
Dr. Inzucchi has a large academic clinical practice involving a wide spectrum of patients with endocrine diseases, with a focus on diabetes and pituitary/adrenal diseases. His current research interests include anti-hyperglycemic therapy in both the inpatient and outpatient settings and the link among type 2 diabetes, insulin resistance, and cardiovascular complications.
Professor of Medicine, Yale University School of Medicine; Clinical Chief, Section of Endocrinology; Program Director, Endocrinology and Metabolism Fellowship; Director, Yale Diabetes Center, New Haven, Connecticut.
MD: Harvard Medical School
Fellowship (endocrinology and metabolism): Yale–New Haven Hospital, New Haven, Connecticut
Clinical Interests: Anti-hyperglycemic therapy; the link among type 2 diabetes, insulin resistance, and cardiovascular complications
The following are Dr. Silvio Inzucchi's disclosures:
Advisor: Merck, vTv Therapeutics, Abbott/Alere, Zafgen
Clinical Trial Steering/Executive/Publications Committee Member and related consulting activities: AstraZeneca, Boehringer Ingelheim, Sanofi/Lexicon, Novo Nordisk
Recent Contributions to PracticeUpdate:
- The Risk of Acute Pancreatitis After Initiation of DPP-4 Inhibitors
- Rising Economic Costs of Diabetes
- PCSK9 Monoclonal Antibodies Do Not Significantly Affect New-Onset Diabetes or Glucose Metabolism
- Optimization of Follow-Up After Metabolic Surgery
- Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults
- Achievement of Guideline Targets for Blood Pressure, Lipid, and Glycemic Control in Type 2 Diabetes
- Adjusted-Dose Metformin Appears Safe in Patients With Type 2 Diabetes and Chronic Kidney Disease Stage 3 or 4
- 2017 Top Stories in Diabetes: CANVAS Study
- Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients With Coronary Heart Disease and Impaired Glucose Tolerance
- Effects on the Incidence of Cardiovascular Events With the Addition of Pioglitazone vs Sulfonylureas in Type 2 Diabetes Inadequately Controlled With Metformin